Literature DB >> 18453248

Cell surface markers in human embryonic stem cells.

Raj R Rao1, Alison Venable Johnson, Steven L Stice.   

Abstract

The pluripotent nature of human embryonic stem cells (hESCs) is based on their potential to form every cell type in the body. Prior to use in directed differentiation strategies, these cells need to be thoroughly characterized. The large number of glycoproteins and carbohydrates that exist on the cell surface provide an excellent opportunity for characterizing hESCs and a means to delineate pluripotent and differentiated cell types. A panel of 14 lectins, based on their specificity for a variety of carbohydrates and carbohydrate linkages, along with stage-specific embryonic antigen-4 (SSEA-4), have been chosen to examine hESCs for other potential pluripotent markers. These studies have been achieved by binding quantitation by flow cytometry and binding localization in adherent colonies by immunocytochemistry. We have shown that certain lectins may be used as markers that are associated with the pluripotent state of hESCs because binding percentages and binding localization of these lectins are similar to those of SSEA-4. This presents options for systematic classification of pluripotent hESCs and for distinguishing differentiated hESC types based on glycan presentation that accompanies differentiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18453248     DOI: 10.1007/978-1-59745-536-7_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

Review 1.  Immunomodulation in stem cell differentiation into neurons and brain repair.

Authors:  Henning Ulrich; Isis Cristina do Nascimento; Jozsef Bocsi; Attila Tárnok
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

2.  Immunocytochemical analysis of human pluripotent stem cells using a self-made cytospin apparatus.

Authors:  Enrique Y Pascual; Marion J Riggs; Raj R Rao
Journal:  J Vis Exp       Date:  2010-04-09       Impact factor: 1.355

Review 3.  Carbohydrate engineered cells for regenerative medicine.

Authors:  Jian Du; Kevin J Yarema
Journal:  Adv Drug Deliv Rev       Date:  2010-02-01       Impact factor: 15.470

Review 4.  Hematopoietic stem cells and solid organ transplantation.

Authors:  Reza Elahimehr; Andrew T Scheinok; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2016-08-03       Impact factor: 3.943

5.  mRNA Reprogramming of T8993G Leigh's Syndrome Fibroblast Cells to Create Induced Pluripotent Stem Cell Models for Mitochondrial Disorders.

Authors:  Harrison E Grace; Patrick Galdun; Edward J Lesnefsky; Franklin D West; Shilpa Iyer
Journal:  Stem Cells Dev       Date:  2019-05-20       Impact factor: 3.272

6.  Enrichment and expansion of cells using antibody-coated micropallet arrays.

Authors:  Hamed Shadpour; Christopher E Sims; Nancy L Allbritton
Journal:  Cytometry A       Date:  2009-07       Impact factor: 4.355

7.  TRA-1-60+, SSEA-4+, Oct4A+, Nanog+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Ovaries.

Authors:  Marek Malecki; Mark Anderson; Michael Beauchaine; Songwon Seo; Xenia Tombokan; Raf Malecki
Journal:  J Stem Cell Res Ther       Date:  2012-11-18

8.  Phasor fluorescence lifetime microscopy of free and protein-bound NADH reveals neural stem cell differentiation potential.

Authors:  Chiara Stringari; Jamison L Nourse; Lisa A Flanagan; Enrico Gratton
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

9.  Differing lectin binding profiles among human embryonic stem cells and derivatives aid in the isolation of neural progenitor cells.

Authors:  Mahesh C Dodla; Amber Young; Alison Venable; Kowser Hasneen; Raj R Rao; David W Machacek; Steven L Stice
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

10.  C9ORF135 encodes a membrane protein whose expression is related to pluripotency in human embryonic stem cells.

Authors:  Shixin Zhou; Yinan Liu; Yumin Ma; Xiaoyan Zhang; Yang Li; Jinhua Wen
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.